Latest Biotech News

Researchers from MRC Laboratory of Medical Sciences and Imperial College London identified a senescence vulnerability tied to GPX4-dependent ferroptosis. In models of melanoma, prostate and...

Anwita Biosciences and collaborators designed an immune-engaging approach that fuses a checkpoint inhibitor concept with cytokine delivery to address two solid-tumor constraints: inhibitory...

Oruka Therapeutics reported Phase 2 psoriasis data for ORKA-001, a half-life-extended IL-23 monoclonal antibody, with 40 of 63 treated patients (63.5%) achieving PASI 100 at 16 weeks versus 1 of...

Baylor College of Medicine researchers reported in PNAS that blood vessels possess a self-protective defense mechanism that slows or prevents the progression of atherosclerosis. The study...

Boehringer Ingelheim reported Phase 3 results for a glucagon-targeted dual agonist showing 16.6% weight loss, while stopping short of the performance seen with established therapies. The company...

Nucleai and spatial proteomics-focused CRO Sirona Dx partnered to deliver AI-driven spatial proteomics services for biopharma. Sirona Dx will lead assay design, development and validation to...

A randomized international trial led by the University of British Columbia found that starting treatment with a minimally invasive approach for advanced atrial fibrillation reduced the need for...

UK biotech venture capital investment rebounded in Q1 2026, with total sector investment reaching £552 million (about $748 million), according to a report cited from the BioIndustry Association....

Intellia Therapeutics advanced its in vivo CRISPR program for hereditary angioedema, signaling potential FDA momentum after Phase 3 results. The company’s one-time lonvo-z treatment cut hereditary...

Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion to expand its next-generation JAK franchise for myeloproliferative neoplasms. Lilly will gain access to AJ1-11095, a Type II...

Erasca reported preliminary efficacy data for its RAS-targeting oral drug ERAS-0015, reporting tumor shrinkage in 40% of patients with advanced pancreatic cancer and 62% of patients with advanced...

Compass Therapeutics shared additional results from its Companion-002 Phase 2/3 program for the DLL4/VEGF-A bispecific tovecimig in second-line biliary tract cancer. The new data included mixed...

Fred Hutchinson Cancer Center reported a transplantation approach using pooled umbilical cord blood stem cells that achieved a 96% survival rate and eliminated graft-versus-host disease in...

Oruka Therapeutics reported mid-stage psoriasis results for ORKA-001, an IL-23 monoclonal antibody with long-acting potential. In a Phase 2 trial, Oruka said 40 of 63 patients achieved PASI 100 at...

PlaqueTec raised $5 million in an oversubscribed financing round to support its coronary artery disease biomarker effort. The company is running a clinical trial called BIOPATTERN designed to...

Cepheid and other diagnostics players presented updates on rapid multiplex infectious disease testing at ESCMID, including workflow improvements designed to improve diagnostic stewardship....

An international clinical trial led by the University of British Columbia reported results in advanced atrial fibrillation that challenge the default approach of beginning with medication....

Whitehead Institute researchers reported a genome-wide screening platform to identify modifications in producer cells that improve the production and delivery potency of engineered virus-like...

Sun Pharmaceutical agreed to acquire Organon, the Merck spinoff women’s health and biosimilars business, in an all-cash $11.75B deal. The transaction is intended to push Sun toward a top three...

Erasca reported preliminary tumor-shrinking data for its RAS-targeting pill ERAS-0015 in advanced pancreatic and non-small cell lung cancer, describing results that exceeded its expectations. The...